The biological basis of panic disorder

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 10, 1996, Pages 23-33

  Krystal, John H ^a,b   Deutsch, Debra Niehoff ^a,c   Charney, Dennis S ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Biotext Medical Communications   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 5 HYDROXYTRYPTOPHAN; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CARBON DIOXIDE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CLONIDINE; DIAZEPAM; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IMIPRAMINE; LACTIC ACID; MONOAMINE OXIDASE INHIBITOR; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; ONDANSETRON; RITANSERIN; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TETRAGASTRIN; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; UNINDEXED DRUG; YOHIMBINE;

ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NEUROANATOMY; NEUROCHEMISTRY; NONHUMAN; NORADRENERGIC SYSTEM; ORAL DRUG ADMINISTRATION; PANIC; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROVOCATION TEST; SEROTONINERGIC TRANSMISSION;

BRAIN; CAFFEINE; CARBON DIOXIDE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LACTATES; NOREPINEPHRINE; PANIC DISORDER; PIPERAZINES; SEROTONIN; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0029803898     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Charney DS, Krystal JH, Southwick SM, et al. Serotonin function in panic and generalized anxiety disorders. Psychiatric Annals 1990;20:593-602
2. Parent A, Descarries L, Beaudet A, et al. Organization of ascending serotonergic systems in the adult rat brain: a radioautographic study after intraventricular administration of (3H)-5-hydroxytryptamine. Neuroscience 1981;6:115-138
3. Steinbusch HWM. Distribution of serotonin immunoreactivity in the central nervous system of the rat: cell bodies and terminals. Neuroscience 1981;6:557-618
4. Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain, III: autoradiographic mapping of serotonin-1 receptors. Neuroscience 1987;21:97-122
5. Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain, IV: autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987;21:123-139
6. Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment: implications for the etiology and therapy of depression. Arch Gen Psychiatry 1981;38:1160-1180
7. Charney DS, Heninger SR. Serotonin function in panic disorders: the effect of intravenous tryptophan in healthy subjects and patients with panic disorder before and during alprazolam treatment. Arch Gen Psychiatry 1988; 43:1059-1065
8. Den Boer JA, Westenberg HGM. Behavioral, neuroendocrine and biochemical effects of 5-HTP administration in panic disorder. Psychiatry Res 1990;31:267-278
9. Targum SD, Marshall LE. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 1989;28:295-306
10. Kahn RS, Wetzler S. m-Chlorophenyl piperazine as a probe of serotonin function. Biol Psychiatry 1991;30:1139-1166
11. 7 receptor subtype. J Biol Chem 1993;268: 18200-18204
12. 1: recognition sites. J Recept Res 1988;8:59-81
13. Charney DS, Woods SW, Goodman WK, et al. Serotonin function in anxiety, II: effects of the serotonin agonist m-CPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl) 1987;92:14-24
14. Kahn R, Asnis C, Wetzler S, et al. Neuroendocrine evidence for a serotonin receptor supersensitivity in panic disorder. Psychopharmacology (Berl) 1988;96:360-364
15. Kahn R, Wetzler S, Van Praag HM, et al. Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Res 1988;25: 101-104
16. Charney DS, Woods SW, Krystal JH, et al. Neurobiological mechanisms of human anxiety. In: Pohl R, Gershon S, eds. The Biological Basis of Psychiatric Treatment Progress in Basic Clinical Pharmacology, vol 3. Basel, Switzerland: Karger;1990:242-283
17. Foote SL, Bloom FE, Aston-Jones G. Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. Physiol Rev 1983;63: 844-914
18. Redmond DE Jr, Huang YH, Snyder DR, et al. Behavioral effects of stimulation of the locus coeruleus in the stumptail monkey (Macaca arctoides). Brain Res 1976;116:502-510
19. Charney DS, Heninger GR. Abnormal regulation of noradrenergic function in panic disorders. Arch Gen Psychiatry 1986;43:1042-1054
20. Abelson JL, Glitz D, Cameron OG, et al. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry 1991;48:157-162
21. Uhde TW, Vittone BJ, Siever LJ, et al. Blunted growth hormone response to clonidine in panic disorder patients. Biol Psychiatry 1986;21:1081-1085
22. Brown SL, Charney DS, Woods SW, et al. Lymphocyte β-adrenergic receptor binding in panic disorder. Psychopharmacology (Berl) 1988;94:24-28
23. Charney DS, Woods SW, Krystal JH. Noradrenergic neuronal dysfunction in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand 1992;86:273-282
24. Charney DS, Heninger GR, Breier A. Noradrenergic function in panic anxiety: effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1984;41:751-763
25. Gurguis GNM, Uhde TW. Plasma 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and growth hormone responses to yohimbine in panic disorder patients and normal controls. Psychoneuroendocrinology 1990; 15:217-224
26. Charney DS, Woods SW, Heninger GR, et al. Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder. Psychiatry Res 1987;27: 173-182
27. Germine M, Goddard AW, Woods SW, et al. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biol Psychiatry 1992;32:457-461
28. Csonka E, Fekete M, Nagy G, et al. Anxiogenic effect of cholecystokinin in rats. In: Penke B, Kovaks K, eds. Peptides. New York, NY: W de Gruyter & Co; 1988:249-252
29. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch Gen Psychiatry 1989;46:511-517
30. Bradwejn J, Koszycki D, Meterissian G. Cholecystokinin tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 1990;35:83-85
31. Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. Arch Gen Psychiatry 1991;48:603-610
32. Nutt D, Lawson C. Panic attacks: a neurochemical overview of models and mechanisms. Br J Psychiatry 1992;160:165-178
33. Woods SW, Charney DS, Loke J, et al. Carbon dioxide sensitivity in panic anxiety: ventilatory and anxiogenic responses to carbon dioxide in healthy subjects and patients with panic anxiety before and after alprazolam treatment. Arch Gen Psychiatry 1986;43:900-909
34. Cohen ME, White PD. Life situations, emotions, and neurocirculatory aesthenia. Psychosom Med 1951;13:355-357
35. Gorman JM, Askanazi J, Liebowitz MR. Response to hyperventilation in patients with panic disorder. Am J Psychiatry 1984;141:857-861
36. 2 and hyperventilation in patients with panic disorder. Am J Psychiatry 1994;151: 547-553
37. Papp LA, Klein DF, Martinez J, et al. Diagnostic and substance specificity of carbon-dioxide-induced panic. Am J Psychiatry 1993;150:250-257
38. Pitts JR Jr, McClure JN Jr. Lactate metabolism in anxiety neurosis. N Engl J Med 1967;277:1328-1336
39. Liebowitz MR, Gorman JM, Fyer AJ, et al. Lactate provocation of panic attacks, II: biochemical and physiological findings. Arch Gen Psychiatry 1984;42:709-719
40. Dorow R, Horowski R, Paschelke G, et al. Severe anxiety induced by FG 7142, a beta-carboline ligand for benzodiazepine receptors. Lancet 1983; 2:98-99
41. Charney DS, Heninger GR, Jatlow PI. Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry 1985;42:233-243
42. Snyder SH, Sklar P. Behavior and molecular actions of caffeine: focus on adenosine. J Psychiatr Res 1984;18:91-106
43. Charney DS, Heninger GR. Noradrenergic function and the mechanisms of action of antianxiety treatment, II: the effect of long-term imipramine treatment. Arch Gen Psychiatry 1985;42:473-481
44. Charney DS, Heninger GR. Noradrenergic function and mechanisms of action of antianxiety treatment, I: the effect of long-term alprazolam treatment. Arch Gen Psychiatry 1986;43:1059-1065
45. Bradwejn J, Koszycki D. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry 1994;151:261-263
46. Liebowitz MR, Fyer AJ, Gorman JM, et al. Alprazolam in the treatment of panic disorders. J Clin Psychopharmacol 1986;6:13-20
47. 2-provoked panic in patients with panic disorder. Am J Psychiatry 1994;151: 1220-1222
48. Woods SW, Charney DS, Delgado PL, et al. The effect of long-term imipramine treatment on carbon dioxide-induced anxiety in panic disorder patients. J Clin Psychiatry 1990;51:505-507
49. Seibyl JP, Krystal JH, Price LH, et al. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. Psychiatry Res 1991;38:227-236
50. Bradwejn J, Koszycki D, Covëtoux du Terre A, et al. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 1994;51:486-493
51. Coplan JD, Liebowitz MR, Gorman JM. Noradrenergic function in panic disorder: effects of intravenous clonidine pretreatment on lactate-induced panic. Biol Psychiatry 1992;31:135-146
52. Woods SW, Krystal JH, Heninger GR, et al. Effects of alprazolam and clonidine on carbon dioxide-induced increases in anxiety ratings in healthy human subjects. Life Sci 1989;45:233-242
53. Goddard AW, Woods SW, Sholomskas DE, et al. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res 1993;48:119-133
54. Charney DS, Heninger GR, Redmond DE Jr. Yohimbine-induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci 1983;33:19-29
55. Sevy S, Brown SL, Wetzler S, et al. Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenyl piperazine. Psychiatry Res 1994;53:219-229
56. 3 antagonist, BRL 46470 does not attenuate m-chlorophenyl piperazine (mCPP)-induced changes in human volunteers. Biol Psychiatry 1994;36:206-210
57. 2 in healthy first-degree relatives of patients with panic disorder. Am J Psychiatry 1995;152:623-625
58. Cowley DS, Dunner DL. Response Io sodium lactate in panic disorder: relationship to presenting clinical variables. Psychiatry Res 1988;25: 253-259
59. Balon R, Jordan M, Pohl R, et al. Family history of anxiety disorders in control subjects with lactate-induced panic attacks. Am J Psychiatry 1989; 146:1304-1306
60. Reiman EM, Raichle ME, Butler FK, et al. A focal brain abnormality in panic disorder: a severe form of anxiety. Nature 1984;310:683-685
61. Reiman EM, Raichle ME, Robins E, et al. Neuroanatomical correlates of a lactate-induced anxiety attack. Arch Gen Psychiatry 1989;46:493-500
62. Reiman EM, Fusselman MJ, Fox PT, et al. Neuroanatomical correlates of anticipatory anxiety. Science 1989;243:1071-1074
63. 4-induced panic attacks in normal volunteers. Presented at the annual meeting of the American College of Neuropsychopharmacology; December 1991; San Juan, Puerto Rico. Abstract 150
64. Drevets WC, Videen TO, MacLeod AK, et al. PET images of blood flow changes during anxiety: correction. Science 1992;256:1696
65. Gur RC, Gur RE, Resnick SM, et al. The effect of anxiety on cortical cerebral blood flow and metabolism. J Cereb Blood Flow Metab 1987;7: 173-177
66. Naveteur J, Roy JC, Ovelac E, et al. Anxiety, emotion, and cerebral blood flow. Int J Psychophysiol 1992;13:137-146
67. Fredrikson M, Wik G, Greitz T, et al. Regional cerebral blood flow during experimental phobic fear. Psychophysiology 1993;30:126-130
68. Rauch SL, Savage CR, Alpert NM, et al. A positron emission tomographic study of simple phobic symptom provocation. Arch Gen Psychiatry 1995; 52:20-28
69. Wu JC, Buchsbaum MS, Hershey TG, et al. PET in generalized anxiety disorder. Biol Psychiatry 1991;29:1181-1199
70. DeCristofaro MTR, Sessarego A, Pupi A, et al. Brain perfusion abnormalities in drug-naive, lactate-sensitive panic patients: a SPECT study. Biol Psychiatry 1993;33:505-512
71. Stewart RS, Devous MD, Rush AJ, et al. Cerebral blood flow changes during sodium-lactate-induced panic attacks. Am J Psychiatry 1988;145: 442-449
72. Woods SW, Koster K, Krystal JH. Yohimbine alters regional cerebral blood flow in panic disorder. Lancet 1988;2:678
73. 4-induced anxiety in normal healthy volunteers. Am J Psychiatry 1995;152:1180-1184
74. Schlegel S, Steinert H, Bockisch A, et al. Decreased benzodiazepine receptor binding in panic disorder measured by iomazenil-SPECT. Eur Arch Psychiatry Clin Neurosci 1994;244:49-51
75. Volkow ND, Tancredi LR. Biological correlates of mental activity studied with PET. Am J Psychiatry 1991;148:439-443
76. McCarthy G, Puce A, Constable RT, et al. Activation of human prefrontal cortex during spatial and object working memory tasks measured by functional MRI. Cereb Cortex. In press